immune inducer

An immune inducer, amino acid technology, used in vaccines, lung cancer vaccines, kidney cancer vaccines, etc.

Active Publication Date: 2022-07-22
TORAY IND INC
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report that the MRAP2 protein has immunity-inducing activity on cancer cells, and thus the protein is useful for the treatment and prevention of cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • immune inducer
  • immune inducer
  • immune inducer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0103] (Example 1) Obtaining novel cancer antigen protein by SEREX method

[0104] (1) Preparation of cDNA library

[0105] Total RNA was extracted from canine testis by the acid guanidium-phenol-chloroform method (Acid guanidium-Phenol-Chloroform method), and polyadenosine was purified using Oligotex-dT30 mRNA furification Kit (manufactured by Takara Shuzo Co., Ltd.) according to the protocol attached to the kit acid RNA.

[0106] A cDNA phage library was synthesized using the obtained mRNA (5 μg). For the preparation of the cDNA phage library, cDNA Synthesis Kit, Zap-cDNA Synthesis Kit, and ZAP-cDNA GigapackIII Gold Cloning Kit (manufactured by STRATAGENE) were used, and the library was prepared according to the protocol attached to the kit. The size of the prepared cDNA phage library is 1×10 6 pfu / ml.

[0107] (2) Screening cDNA library by serum

[0108] Immunoscreening was performed using the cDNA phage library prepared above. Specifically, the host Escherichia coli ...

Embodiment 2

[0116] (Example 2) Analysis of cancer antigenicity of MRAP2 in vivo

[0117] (1) Production of recombinant vector expressing mouse MRAP2 in vivo

[0118] Based on the nucleotide sequence of SEQ ID NO: 7, a recombinant vector expressing mouse MRAP2 in vivo was prepared by the following method. PCR was performed with 1 μl of cDNA prepared from the mouse leukemia cell line EL4 (purchased from ATCC) whose expression was observed in Example 1, and two primers (described in SEQ ID NOs: 17 and 18) containing EcoRI and NotI restriction sequences. 0.4 μM, 0.2 mM dNTP, 1.25 U each of PrimeSTAR HS polymerase (manufactured by Takara Shuzo Co., Ltd.) were added to make the total amount of each reagent and buffer solution 50 μl, and a thermal cycler (manufactured by BIO RAD) was used to heat the mixture at 98° C. for 10 The cycle of seconds, 55°C for 15 seconds, and 72°C for 1 minute was repeated 30 times. In addition, the above-mentioned two kinds of primers are primers for amplifying th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a novel immunity-inducing agent for the treatment and / or prevention of cancer, in particular to a polypeptide comprising at least one polypeptide selected from the group consisting of polypeptides derived from MRAP2 and variants thereof and having immunity-inducing activity, or a polypeptide encoding the same An immunity-inducing agent using a recombinant vector capable of expressing the polypeptide in vivo as an active ingredient, and an immunity-inducing method comprising the step of administering the immunity-inducing agent to a subject.

Description

technical field [0001] The present invention relates to novel immunity-inducing agents useful as cancer therapeutics and / or preventives. Background technique [0002] Cancer is the leading cause of death, and the current treatment is surgery, combined with radiotherapy and chemotherapy. Despite the development of new surgical methods and the discovery of new anticancer agents in recent years, the current situation is that, except for some cancers, the results of cancer treatment have not been greatly improved. In recent years, with advances in molecular biology and cancer immunology, cancer antigens recognized by cytotoxic T cells that respond to cancer, genes encoding cancer antigens, and the like have been identified, leading to expectations for antigen-specific immunotherapy improve. [0003] Melanocortin 2 receptor accessory protein 2 (melanocortin 2 receptor accessory protein, MRAP2) is a type 1 or type 2 transmembrane protein that participates in the control of melan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/00C07K14/705C12N15/09A61K39/39A61K48/00A61P35/00A61P35/02A61P37/04C07K14/54C07K14/555
CPCC07K14/54C07K14/555A61K2039/53A61K2039/55555A61K2039/828A61K2039/892A61K2039/868A61K2039/844A61K2039/852A61K2039/86A61K39/001102C07K14/70596A61P35/00C07K14/4748C12N15/62A61K35/15A61K38/20A61K38/21A61K39/39A61K48/005C07K14/705A61K35/76A61K38/17A61P37/04A61K39/00C12N15/09
Inventor 藤田贵之冈野文义
Owner TORAY IND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap